创新许可：利用 Oracle 的智能人工智能最大化业务价值 [PAN3799].pdf

《创新许可：利用 Oracle 的智能人工智能最大化业务价值 [PAN3799].pdf》由会员分享，可在线阅读，更多相关《创新许可：利用 Oracle 的智能人工智能最大化业务价值 [PAN3799].pdf（9页珍藏版）》请在三个皮匠报告上搜索。

1、About GlaukosTransforming the treatment of chronic eye diseases with novel therapies that provide sustainable solutions to important clinical needs.Founded in 1998,Glaukos Corporation is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glauc

2、oma,corneal disorders,and retinal diseasesFirst company to bring to market Micro-Invasive Glaucoma Surgery(MIGS),the micro-invasive procedure which revolutionized the treatment and management of glaucomaIn 2012,we launched our first MIGS devicethe iStentin the United States,followed by our next-gene

3、ration iStent inject device in September 2018With direct sales operations in 17 countries,we employ more than 200 commercial sales personnel worldwideAliso Viejo,CAHeadquartersYear founded19982015Year IPOEmployees Worldwide1200+Complete SolutionsiDose TR(travoprost intracameral implant)75 mcg is a p

4、rocedural pharmaceutical that delivers prostaglandin analog therapy for the reduction of intraocular pressure in patients with open-angle glaucoma orocular hypertension.Its a first-of-its-kind anchored implant designed to deliver continuous drugtherapy.GlaucomaCorneal HealthRetinal DiseasesDevelopin

5、g Sustained-Release Drug Delivery Platforms for Retinal DiseasesRetinal diseases vary widely,can affect any part of the retina and are leading causes of blindness worldwide.Glaukos is developing multiple micro-invasive,bioerodible,sustained-release drug delivery platforms designed to be used in the

6、treatment of various retinal diseases,including age-related macular degeneration(AMD)and diabetic macular edema.Advancing the field of corneal remodelingWere transforming the standard of care for progressive keratoconus through our commitment to addressing imp